John R. White

John R. White

Auto-generated profile, based on publicly available information

John R. White

Analytical Development, GlaxoSmithKline Research & Development, 1250 S Collegeville Road, Collegeville, PA19426, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2001
Verified
Book Chapter
Closed access
PDF file
HSHenry M. Sarau
Henry M. Sarau
KWKatherine L. Widdowson
Katherine L. Widdowson
MPMichael R. Palovich
Michael R. Palovich
JWJohn R. White
John R. White
DUDavid C. Underwood/Surname
David C. Underwood/Surname
DGDon E. Griswold
Don E. Griswold

1 January 2006 in Nuclear Technology and Radiation Protection
Verified
Journal Article
Open access
ABAnis Bousbia-Salah
Anis Bousbia-Salah
AJAreeya Jirapongmed
Areeya Jirapongmed
THTewfik Hamidouche
Tewfik Hamidouche
JWJohn White
John White
FDFrancesco S. D'auria
Francesco S. D'auria
MAMartina Adorni
Martina Adorni
RELAP5 is a system code developed at the Idaho National Environmental and Engineering Laboratory for thermal hydraulic analysis of nuclear reactors. The code RELAP5 is widely used for safety analysis studies of commercial nuclear power plants. However, recent released version of RELAP5/3.2 and over present significant capabilities for analysis of nuclear reactor research systems. As a contribution to the assessment of RELAP5/3.3 for research reactor safety analysis, experimental data from the University of Massachusetts Lowell Research Reactor - UMLRR are used. The UMLRR is a 1 MW light water moderated and cooled, graphite-reflected, open-pool type research reactor. This paper presents the development and the validation of a UMLRR-RELAP model using experimental data. For this purpose, a series of experiments were performed for benchmarking RELAP5 calculations for research reactor systems. As a result of this study, the UMLRR nodalization is shown to be representative of the experimental data reactor behavior.

1 March 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ATAndrew S. Thomson
Andrew S. Thomson
SMShing H. Mai
Shing H. Mai
GBGerben Bouma
Gerben Bouma
MHMichael Herdman
Michael Herdman
MBMichael Byrne
Michael Byrne
SCShugui Chen
Shugui Chen
MAbs have revolutionized the treatment of autoimmune disorders. Even though mAbs have shown impressive efficacy in blocking T cell or B cell activation and/or recruitment to sites of inflammation, this group of biologicals are not devoid of adverse effects. The most serious adverse effects include infusion reactions, including the activation of the complement pathway. In this study, we present a detailed structure–function study of an anti-CCL20 humanized IgG1 mAb that neutralizes CCL20 chemokine and prevents the recruitment of Th17 cells to sites of inflammation. We demonstrate that the anti-CCL20 Ab changes significantly following administration to humans and monkeys and exposure to human serum. Analysis of the drug product revealed that the anti-CCL20 Ab has unexpectedly high C1q binding. This high binding was linked to immune complex formation in vivo but not during in vitro serum incubation. The immune complex contained multiple complement components. Anti-CCL20 Ab-mediated, complement-dependent cytotoxicity occurred when the Ab bound to CCL20 tethered to the cell membrane of target cells. Taken together, these results provide a likely cause for the animal toxicity observed. In addition, anti-CCL20 revealed progressive acidification because of N100 (located in CDR) deamidation over time, which did not directly impact Ag binding. Our study demonstrates that the safety profiling of mAbs should include the evaluation of effector functions in addition to typical stressed conditions.

9 February 2024 in BioTechniques
Verified
Journal Article
Open access
JWJohn R White
John R White
SASammina Ahmed
Sammina Ahmed
JAJan Amstrup
Jan Amstrup
PBPetra Bennington
Petra Bennington
ZCZhijie Jey Cheng
Zhijie Jey Cheng
JWJenny Wang
Jenny Wang
The BioPhorum Development Group is an industry collaboration enabling the sharing of common practices for the development of biopharmaceuticals. Bioassays are an important part of an analytical con... Method summary Draft questions were composed by the authors based on prior knowledge of the issues associated with ready-to-use cell use. Questions were further refined through open discussion amon...

28 August 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JMJianhong Ma
Jianhong Ma
QLQi Liu
Qi Liu
JWJohn R. White
John R. White
Lack of simple and robust methods to determine complement activation in human serum induced by antigen-antibody complexes is a major hurdle for monitoring therapeutic antibody drug quality and stability. Dezamizumab is a humanized IgG1 monoclonal antibody that binds to serum amyloid P component (SAP) for potential treatment of systemic amyloidosis. The mechanism of action of Dezamizumab includes the binding of SAP, complement activation through classical pathway, and phagocytosis; however, the steps in this process cannot be easily monitored. We developed two novel methods to determine Dezamizumab-SAP complex-induced complement activation. Complement component 3 (C3) depletion was detected by homogeneous time-resolved fluorescence (HTRF), and C3a desArg fragment, formed after the cleavage of C3 to yield C3a followed by removal of its C-terminal arginine residue, was determined using Meso Scale Discovery (MSD) technology. We found that the presence of both Dezamizumab and SAP was required for complement activation via both methods. The optimal molar ratio of Dezamizumab:SAP was 6:1 in order to obtain maximal complement activation. The relative potency from both methods showed a good correlation to Dezamizumab-SAP-dependent complement component 1q (C1q) binding activity in Dezamizumab thermal-stressed samples. Both SAP and C1q binding, as determined by surface plasmon resonance and the two complement activation potency methods described here, reflect the mechanism of action of Dezamizumab. We conclude that these methods can be used to monitor Dezamizumab quality for drug release and stability testing, and the novel potency methods reported here can be potentially used to evaluate complement activity induced by other antigen-antibody complexes.